Nimbus Therapeutics will have $43 million to progress clinical trials of its non-alcoholic liver disease drug after the company successfully completed a financing round.
The Series B investment was led by Pfizer Venture Investments and Lightstone Ventures. Previous investors, including Atlas Venture, SR One, Lilly Ventures and Bill Gates, also participated.
{iframe}http://www.bizjournals.com/boston/blog/health-care/2015/03/nimbus-therapeutics-begins-liver-disease-trials.html{/iframe}